JKA
VRTX icon

Jones Kertz & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Jones Kertz & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
3,729
-275
-7% -$122K 0.85% 32
2026
Q1 		$1.79M Hold
4,004
– – 0.95% 32
2025
Q4 		$1.82M Buy
+4,004
New +$1.73M 0.93% 30

Other funds holding VRTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Jones Kertz & Associates's VRTX Position: Q2 2026 in Review

Jones Kertz & Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 6.9% in Q2 2026, selling an estimated $122K and leaving 3,729 shares worth $1.85M. The position accounts for 0.85% of the portfolio, ranked #32.

Jones Kertz & Associates first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 947 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Jones Kertz & Associates held 3,729 shares of Vertex Pharmaceuticals worth $1.85M as of Q2 2026.
  • Jones Kertz & Associates sold 275 Vertex Pharmaceuticals shares in Q2 2026, an estimated $122K.
  • Vertex Pharmaceuticals made up 0.85% of Jones Kertz & Associates's portfolio in Q2 2026, its #32 holding.
  • Jones Kertz & Associates first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 947 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Jones Kertz & Associates's 13F filing for Q2 2026, filed 23 Jul 2026.